GW Pharma (GWPH) Epidiolex Data in LGS 'Looks Good' - Leerink

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. USO
2. MRVL
3. SPY
4. BBIO
5. NVDA
6. GOOGL
7. OPCH
8. CHRW
9. AMD
10. STZ

Go back to GW Pharma (GWPH) Epidiolex Data in LGS 'Looks Good' - Leerink

GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

June 27, 2016 7:00 AM EDT

- Primary endpoint achieved with high statistical significance (p=0.0135) showing that Epidiolex treatment reduces drop seizures compared to placebo -

- Todays LGS data follows successful Phase 3 trial in Dravet syndrome announced in March 2016 -

- Company to hold investor conference call today at 8:00 a.m. EDT/13:00 BST -

LONDON, June 27, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (AIM: GWP) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and... More